Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth (original) (raw)
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells
Ana-Maria Florea
Journal of Neurochemistry, 2012
View PDFchevron_right
Review The Medicinal Chemistry of Imidazotetrazine Prodrugs
Richard Wheelhouse
2014
View PDFchevron_right
99mTc-radiolabeled imidazo[2,1-b]benzothiazole derivatives as potential radiotracers for glioblastoma
Fereshteh Talebpour Amiri
Journal of Radioanalytical and Nuclear Chemistry, 2019
View PDFchevron_right
Extended-schedule dose-dense temozolomide in refractory gliomas
Miguel Angel Garcia Gil
Journal of Neuro-Oncology, 2009
View PDFchevron_right
The Medicinal Chemistry of Imidazotetrazine Prodrugs
Richard Wheelhouse
Pharmaceuticals, 2014
View PDFchevron_right
In search of effective therapies to overcome resistance to Temozolomide in brain tumours
Cancer Drug Resistance
Cancer Drug Resistance, 2019
View PDFchevron_right
Protracted Adjuvant Temozolomide in Glioblastoma Multiforme
Dina Salem
Journal of Cancer Therapy, 2015
View PDFchevron_right
Novel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer Cells
Sakthivel Muniyan
PLOS ONE, 2015
View PDFchevron_right
Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma
Giacomo Signorino
Oncotarget, 2017
View PDFchevron_right
MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma
Johan Kros
The New England Journal of Medicine, 2005
View PDFchevron_right
DDRE-25. Novel Temozolomide Analogs to Improve Anti-Tumor Efficacy and Overcome Resistance in Glioblastoma Multiforme
Venkata Yenugonda
Neuro-Oncology, 2020
View PDFchevron_right
Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status
Eleni Efstathiou
Medical Oncology, 2000
View PDFchevron_right
Temozolomide analogs with improved brain/plasma ratios – exploring the possibility of enhancing the therapeutic index of temozolomide
Eduardo Riquelme
Bioorganic & Medicinal Chemistry Letters, 2016
View PDFchevron_right
Design, Synthesis and Studies of Novel Imidazoles
Swastika Ganguly
ECSOC-25
View PDFchevron_right
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials
Richard Wheelhouse
Cancer Treatment Reviews, 1997
View PDFchevron_right
Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma
Ting-Chao Chou
Cancer Gene Therapy, 2001
View PDFchevron_right
Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner
Jacek Jassem
Clinical Cancer Research, 2014
View PDFchevron_right
Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study
Jannick Brennum
Molecular Oncology, 2021
View PDFchevron_right
In Vitro Evaluation of the Multidrug Resistance Reversing Activity of Novel Imidazo[4,5-b]pyridine Derivatives
Selma Bourichi
Anticancer Research, 2018
View PDFchevron_right
Synthesis of novel thiazolidine-4-one derivatives and their anticancer activity
Nosrat Mahmoodi
Phosphorus, Sulfur, and Silicon and the Related Elements, 2016
View PDFchevron_right
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas
Naoko Takebe
Oncotarget, 2020
View PDFchevron_right
Synthesis and biological evaluation of novel imidazolone derivatives as potential COX-2 inhibitors
Magda Ismail
Archives of Pharmacal Research, 2008
View PDFchevron_right
{"__content__"=>"Synthesis and growth-inhibitory activities of imidazo[5,1-]-1,2,3,5-tetrazine-8-carboxamides related to the anti-tumour drug temozolomide, with appended silicon, benzyl and heteromethyl groups at the 3-position.", "i"=>{"__content__"=>"d"}}
Richard Wheelhouse
MedChemComm, 2018
View PDFchevron_right
Anti-tumor activity of lipophilic imidazolium salts on select NSCLC cell lines
Wiley Youngs
Medicinal Chemistry Research, 2015
View PDFchevron_right
The SIAH1–HIPK2–p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death
Bernd Kaina
Molecular Cancer Research, 2019
View PDFchevron_right
Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents
Heng Lin
Investigational New Drugs, 2010
View PDFchevron_right
On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent Resistance
Aleksei A Stepanenko
Biomedicines
View PDFchevron_right
Going past the data for temozolomide
Nathalie Letarte
Cancer Chemotherapy and Pharmacology, 2011
View PDFchevron_right
Temozolomide and tranilast synergistic antiproliferative effect on human glioblastoma multiforme cell line (U87MG)
Mona Pazhouhi
Medical Journal of The Islamic Republic of Iran
View PDFchevron_right
Synthesis and antiproliferative activity of thiazolidine analogs for melanoma
Gordana Bogdanovic
Bioorganic & Medicinal Chemistry Letters, 2007
View PDFchevron_right
Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: Phase II study
ALESSANDRO PAPPALARDO
Lung Cancer, 2005
View PDFchevron_right
Imidazoline Receptor System: The Past, the Present, and the Future
J. Garcia-sevilla
Pharmacological Reviews, 2019
View PDFchevron_right
Temozolomide in malignant gliomas: current use and future targets
Linda Bressler
Cancer Chemotherapy and Pharmacology, 2009
View PDFchevron_right